New York, USA, April 19, 2022 (GLOBE NEWSWIRE) -- Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight
Plaque Psoriasis is the most common type of psoriasis and accounts for 80% to 90% cases of total psoriasis. An increase in the number of biologics and biosimilar products has led to enhanced drug development for the treatment of moderate to severe plaque psoriasis. Bristol Myers Squibb is seeking for the market approval of Deucravacitinib with a Prescription Drug User Fee Act (PDUFA) goal date of September 10, 2022. Other companies investigating the potential treatment in the highest stage of development include Jiangsu Hengrui Medicine, Akeso Biopharma, Can-fite biopharma, and several others.
DelveInsight’s 'Moderate to Severe Plaque Psoriasis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Moderate to Severe Plaque Psoriasis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Moderate to Severe Plaque Psoriasis pipeline domain.
Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report
- DelveInsight’s Moderate to Severe Plaque Psoriasis Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
- Leading Moderate to Severe Plaque Psoriasis companies such as Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra, and others are evaluating novel Plaque Psoriasis treatment drugs candidate to improve the treatment landscape.
- Key Moderate to Severe Plaque Psoriasis pipeline therapies in various stages of development includes BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202 , DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772, and others.
- In November 2021, the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 10, 2022.
- In March 2022, Jansen Research and development announced the initiation of VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp PsO.
- The Janssen Pharmaceutical Companies of Johnson & Johnson in March 2022 announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase III VOYAGE 1 and VOYAGE 2 clinical trials.
- In March 2022, Nimbus Therapeutics initiated a Phase Ib clinical trial of its investigational oral allosteric tyrosine kinase 2 inhibitor, NDI-034858, in patients with moderate-to-severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting. NDI-034858 was observed to be generally well-tolerated and no serious adverse events were observed and no trends of adverse events were noted with increasing drug exposure.
- On April 7, 2022, Meiji Seika Pharma dosed first patient in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with moderate to severe Plaque Psoriasis in the United States and Canada.
- Can-Fite in March 2022 announced completed enrollment in its Phase III Comfort™ study for the treatment of moderate-to-severe plaque psoriasis with 400 patients enrolled across 30 sites in Europe, Israel, and Canada. Topline data are expected in Q2 2022.
Request a sample and discover the recent advances in the treatment of Moderate to Severe Plaque Psoriasis @ Moderate to Severe Plaque Psoriasis Pipeline Outlook
The Moderate to Severe Plaque Psoriasis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Moderate to Severe Plaque Psoriasis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Moderate to Severe Plaque Psoriasis pipeline landscape.
Moderate to Severe Plaque Psoriasis Overview
Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Plaques are the thick, scaly spots that appear on the skin. Plaques psoriasis affects around 80% to 90% of patients with psoriasis. It is an autoimmune disorder in which skin cells quickly pile up, causing scales and flaky, dry, itchy areas. Scientists do not completely understand the processes underlying autoimmune disorders such as Moderate to Severe Plaque Psoriasis, although genetics are thought to have a role. Around a third of patients with psoriasis have a family history of the disorder and evidence of chromosomal abnormalities in particular places of a gene (known as PSORS1 through PSORS9). Other causes of Moderate to Severe Plaque Psoriasis include previous infections or toxic exposure, although the majority are speculative at best.
Moderate to Severe Chronic Plaque Psoriasis commonly known as Psoriasis Vulgaris, often manifests as elevated areas of irritated skin covered with silvery-white scales. Moderate to Severe Plaque Psoriasis symptoms can come and go, frequently remaining in remission for months or even years before returning for no apparent cause. In other circumstances, symptoms of plaque psoriasis may be cyclical or even seasonal.
Psoriasis can’t be cured. The patient most often goes through cycles in which the rash improves and then flares up again. The Moderate to Severe Plaque Psoriasis treatment objective is to have fewer and less severe flare-ups. The current options of treatment for plaque psoriasis include topical corticosteroids, phototherapy, vitamin D3 analogs, and retinoids.
Find out more about Moderate to Severe Plaque Psoriasis treatment @ Moderate to Severe Plaque Psoriasis Medications
A snapshot of the Moderate to Severe Plaque Psoriasis Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| BMS-986165 | Bristol-Myers Squibb | Pre-registration | TYK2 kinase inhibitors | Oral |
| SHR 1314 | Jiangsu Hengrui Medicine | Phase III | IL17A protein inhibitors | Subcutaneous |
| Ebdarokimab | Akeso Biopharma | Phase III | Interleukin 23 inhibitors | Subcutaneous |
| Jaktinib | Suzhou Zelgen Biopharmaceuticals | Phase II | Janus kinase 1,2,3 inhibitors | Oral |
| SCD-044 | Sun Pharmaceutical Industries Limited | Phase II | Sphingosine 1 phosphate receptor agonists | Oral |
| Orismilast | Union Therapeutics | Phase II | Type 4 cyclic nucleotide phosphodiesterase inhibitors | Oral |
| NDI 034858 | Nimbus Therapeutics | Phase II | TYK2 kinase inhibitors | Oral |
| ME3183 | Meiji Pharma | Phase II | Type 4 cyclic nucleotide phosphodiesterase inhibitors | Oral |
| CT 303 | GC Cell Corporation | Phase I | Cell replacements | Intravenous |
Learn more about the novel and emerging Moderate to Severe Plaque Psoriasis pipeline therapies @ Moderate to Severe Plaque Psoriasis Clinical Trials
Moderate to Severe Plaque Psoriasis Therapeutics Assessment
The Moderate to Severe Plaque Psoriasis Pipeline report proffers an integral view of the Moderate to Severe Plaque Psoriasis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Topical, Intravitreal, Subretinal
- Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Polymers, Peptides, Monoclonal antibodies
- Therapeutics Assessment By Mechanism of Action: TYK2 kinase inhibitors, IL17A protein inhibitors, Interleukin 23 inhibitors, Janus kinase 1,2,3 inhibitors, Sphingosine 1 phosphate receptor agonists, Cell replacements
- Key Moderate to Severe Plaque Psoriasis Companies: Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, and others.
- Key Moderate to Severe Plaque Psoriasis Pipeline Therapies: BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202 , DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772 and others.
Dive deep into rich insights for drugs for Plaque Psoriasis, visit @ Moderate to Severe Plaque Psoriasis Prescription Drugs
Table of Contents
| 1. | Moderate to Severe Plaque Psoriasis Pipeline Report Introduction |
| 2. | Moderate to Severe Plaque Psoriasis Pipeline Report Executive Summary |
| 3. | Moderate to Severe Plaque Psoriasis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Moderate to Severe Plaque Psoriasis Pipeline Therapeutics |
| 6. | Moderate to Severe Plaque Psoriasis Pipeline: Late Stage Products (Pre-registration) |
| 6.1 | BMS-986165: Bristol-Myers Squibb |
| 7. | Moderate to Severe Plaque Psoriasis Pipeline: Late Stage Products (Phase III) |
| 7.1 | SHR 1314: Jiangsu Hengrui Medicine |
| 8. | Moderate to Severe Plaque Psoriasis Pipeline: Mid Stage Products (Phase II) |
| 8.1 | Orismilast: Union Therapeutics |
| 9. | Moderate to Severe Plaque Psoriasis Pipeline: Early Stage Products (Phase I) |
| 9.1 | CT 303: GC Cell Corporation |
| 10. | Moderate to Severe Plaque Psoriasis Pipeline Therapeutic Assessment |
| 11. | Inactive Products in the Moderate to Severe Plaque Psoriasis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Moderate to Severe Plaque Psoriasis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Moderate to Severe Plaque Psoriasis pipeline therapeutics, reach out @ Moderate to Severe Plaque Psoriasis Drugs
Related Reports
Moderate to Severe Plaque Psoriasis Market
Moderate to Severe Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Moderate to Severe Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Moderate to Severe Plaque Psoriasis Epidemiology Forecast
Moderate to Severe Plaque Psoriasis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted Moderate to Severe Plaque Psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Plaque Psoriasis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Plaque Psoriasis companies involved such as Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, among others.
Chronic Plaque Psoriasis Pipeline
Chronic Plaque Psoriasis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chronic Plaque Psoriasis companies involved such as Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, among others.
Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Mild to Moderate Plaque Psoriasis Market
Mild to Moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Mild to Moderate Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, BMS, among others.
Other Trending Reports
Hepatitis A Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hepatitis A companies involved such as Boryung Pharmaceutical, Cadila Healthcare, among others.
Obsessive-Compulsive Disorder Market
Obsessive-Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Obsessive-Compulsive Disorder companies involved such as Pfizer, GSK, Eli Lilly, among others.
Traveler’s Diarrhea Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Traveler’s Diarrhea companies involved such as Nippon Shinyaku, Immuron, among others.
Cryptococcosis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cryptococcosis companies involved such as Matinas Biopharma, Mycovia Pharmaceuticals, among others.
Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hypertrophic Scar companies involved such as Henry Ford Health System, Gladerma, Phio Pharmaceuticals, among others.
Related Healthcare Blogs
Upcoming Drugs for Autoimmune Diseases
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
